Nektar Therapeutics

1. amlitelimab Sanofi filing2H 2026amlitelimab Sanofi filing, 2H 2026, notable
2. Rezpegaldesleukin trial start2H 2026Rezpegaldesleukin trial start, 2H 2026, routine
3. undisclosed Treg indication trial start2H 2026undisclosed Treg indication trial start, 2H 2026, routine
4. Rezpegaldesleukin AA readout4Q 2026Rezpegaldesleukin AA readout, 4Q 2026, material
5. REZOLVE-AD / REZOLVE-AA corporate updateOct 1, 2026REZOLVE-AD / REZOLVE-AA corporate update, Oct 1, 2026, notable
6. Rezpegaldesleukin AD readout1Q 2027Rezpegaldesleukin AD readout, 1Q 2027, major
7. Rezpegaldesleukin T1D Ph2 interim2027Rezpegaldesleukin T1D Ph2 interim, 2027, notable
8. AA registrational Phase 3 Ph3Early 2027AA registrational Phase 3 Ph3, Early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.